90 related articles for article (PubMed ID: 20675014)
1. Use of warfarin therapy at a target international normalized ratio of 3.0 for cutaneous polyarteritis nodosa.
Kawakami T; Soma Y
J Am Acad Dermatol; 2010 Oct; 63(4):602-6. PubMed ID: 20675014
[TBL] [Abstract][Full Text] [Related]
2. High titer of anti-phosphatidylserine-prothrombin complex antibodies in patients with cutaneous polyarteritis nodosa.
Kawakami T; Yamazaki M; Mizoguchi M; Soma Y
Arthritis Rheum; 2007 Dec; 57(8):1507-13. PubMed ID: 18050170
[TBL] [Abstract][Full Text] [Related]
3. Effect of heart failure exacerbations on anticoagulation: a prospective, observational, pilot cohort study.
Ripley TL; Harrison D; Germany RE; Adamson PB
Clin Ther; 2010 Mar; 32(3):506-14. PubMed ID: 20399987
[TBL] [Abstract][Full Text] [Related]
4. Effect of fixed minidose warfarin, conventional dose warfarin and aspirin on INR and prothrombin fragment 1 + 2 in patients with atrial fibrillation.
Koefoed BG; Feddersen C; Gulløv AL; Petersen P
Thromb Haemost; 1997 May; 77(5):845-8. PubMed ID: 9184390
[TBL] [Abstract][Full Text] [Related]
5. Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies.
Perry SL; Samsa GP; Ortel TL
Thromb Haemost; 2005 Dec; 94(6):1196-202. PubMed ID: 16411394
[TBL] [Abstract][Full Text] [Related]
6. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
[TBL] [Abstract][Full Text] [Related]
7. Comparison between CoaguChek S- and Owren-type prothrombin time assay for monitoring anticoagulant therapy.
Jonsson M; Hillarp A; Svensson P
Thromb Res; 2004; 114(2):83-9. PubMed ID: 15306149
[TBL] [Abstract][Full Text] [Related]
8. Cutaneous polyarteritis nodosa: revisiting its definition and diagnostic criteria.
Nakamura T; Kanazawa N; Ikeda T; Yamamoto Y; Nakabayashi K; Ozaki S; Furukawa F
Arch Dermatol Res; 2009 Jan; 301(1):117-21. PubMed ID: 18802715
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of the switch from a branded to a generic warfarin sodium product: an observer-blinded, randomized, crossover study.
Lee HL; Kan CD; Yang YJ
Clin Ther; 2005 Mar; 27(3):309-19. PubMed ID: 15878384
[TBL] [Abstract][Full Text] [Related]
10. Rapid healing of chronic leg ulcers during perilesional injections of granulocyte-macrophage colony-stimulating factor therapy in a patient with cutaneous polyarteritis nodosa.
Tursen U; Api H; Kaya TI; Cinel L; Ikizoglu G
J Eur Acad Dermatol Venereol; 2006 Nov; 20(10):1341-3. PubMed ID: 17062064
[No Abstract] [Full Text] [Related]
11. Refractory polyarteritis nodosa successfully treated with infliximab.
Al-Bishri J; le Riche N; Pope JE
J Rheumatol; 2005 Jul; 32(7):1371-3. PubMed ID: 15996083
[TBL] [Abstract][Full Text] [Related]
12. Predictors of warfarin use in atrial fibrillation patients in the inpatient setting.
Agarwal S; Bennett D; Smith DJ
Am J Cardiovasc Drugs; 2010; 10(1):37-48. PubMed ID: 20104933
[TBL] [Abstract][Full Text] [Related]
13. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
[TBL] [Abstract][Full Text] [Related]
14. Search for predictors of nontherapeutic INR results with warfarin therapy.
McGriff-Lee NJ; Csako G; Chen JT; Dang DK; Rosenfeld KG; Cannon RO; Macklin LR; Wesley RA;
Ann Pharmacother; 2005 Dec; 39(12):1996-2002. PubMed ID: 16288081
[TBL] [Abstract][Full Text] [Related]
15. Warfarin therapy: evolving strategies in anticoagulation.
Horton JD; Bushwick BM
Am Fam Physician; 1999 Feb; 59(3):635-46. PubMed ID: 10029789
[TBL] [Abstract][Full Text] [Related]
16. Interference of lupus anticoagulants in prothrombin time assays: implications for selection of adequate methods to optimize the management of thrombosis in the antiphospholipid-antibody syndrome.
Della Valle P; Crippa L; Garlando AM; Pattarini E; Safa O; Viganò D'Angelo S; D'Angelo A
Haematologica; 1999 Dec; 84(12):1065-74. PubMed ID: 10586206
[TBL] [Abstract][Full Text] [Related]
17. CYP2C9 genotypes and dose requirements during the induction phase of oral anticoagulant therapy.
Peyvandi F; Spreafico M; Siboni SM; Moia M; Mannucci PM
Clin Pharmacol Ther; 2004 Mar; 75(3):198-203. PubMed ID: 15001971
[TBL] [Abstract][Full Text] [Related]
18. Practical application of the 10-mg warfarin initiation nomogram.
Wells PS; Le Gal G; Tierney S; Carrier M
Blood Coagul Fibrinolysis; 2009 Sep; 20(6):403-8. PubMed ID: 19521238
[TBL] [Abstract][Full Text] [Related]
19. Retrospective evaluation of a possible interaction between warfarin and levofloxacin.
McCall KL; Scott JC; Anderson HG
Pharmacotherapy; 2005 Jan; 25(1):67-73. PubMed ID: 15767222
[TBL] [Abstract][Full Text] [Related]
20. Single-dose adjustment versus no adjustment of warfarin in stably anticoagulated patients with an occasional international normalized ratio (INR) out of range.
Schulman S; Melinyshyn A; Ennis D; Rudd-Scott L
Thromb Res; 2010 May; 125(5):393-7. PubMed ID: 19640572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
